Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Kellner H, Kiltz U, Rech J, Burmester GR, Kofler D, Brandt-Juergens J, Jonetzko C, Burkhardt H, Behrens F (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 4111-4114
Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY
Abstract
Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of csDMARD/MTX before initiation of a biological treatment. The value of MTX in combination with bDMARDs is still unclear. We designed an investigator-initiated, randomized, placebo-controlled trial (IIT) in active PsA to examine if outcomes of treatment with ustekinumab (UST) in combination with MTX (either newly initiated or ongoing) were different from UST only (+Placebo; PBO). The aim of the trial was to evaluate non-inferiority of efficacy on arthritis (DAS28 at W24) and compare efficacy on PsA domains for UST+MTX vs UST+PBO.
Involved external institutions
Goethe-Universität Frankfurt am Main
Germany (DE)
Fraunhofer-Institut für Translationale Medizin und Pharmakologie (ITMP) / Fraunhofer Institute for Translational Medicine and Pharmacology
Germany (DE)
Rheumazentrum Ruhrgebiet
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Germany (DE)
Fraunhofer-Institut für Translationale Medizin und Pharmakologie (ITMP) / Fraunhofer Institute for Translational Medicine and Pharmacology
Germany (DE)
Rheumazentrum Ruhrgebiet
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
How to cite
APA:
Koehm, M., Rossmanith, T., Foldenauer, A.C., Herrmann, E., Kellner, H., Kiltz, U.,... Behrens, F. (2021). Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function. In ARTHRITIS & RHEUMATOLOGY (pp. 4111-4114). HOBOKEN: WILEY.
MLA:
Koehm, Michaela, et al. "Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2021. 4111-4114.
BibTeX: Download